Video Experimental Relacionado
Updated: May 7, 2026
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
15.9K
¿La esteatosis hepática es una enfermedad o la ropa nueva del emperador?
Aleksander Krag1, Frank Tacke2, Mads Israelsen1
1Department of Gastroenterology & Hepatology, Odense University Hospital, 5000 Odense, Denmark; Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark.
Journal of hepatology
|January 19, 2026
Resumen
La enfermedad del hígado graso asociada a disfunción metabólica (MASLD) es común pero rara vez progresa. Solo la esteatohepatitis (MASH) con fibrosis requiere tratamiento específico para el hígado, distinguiéndola de la acumulación benigna de grasa.
Área de la Ciencia:
- Hepatología
- Enfermedades Metabólicas
- Patología Hepática
Sus antecedentes:
- La redefinición de la enfermedad del hígado graso en MASLD y MASH aclara la acumulación benigna de grasa frente a la patología.
- MASLD afecta al 25-30% a nivel mundial, pero solo una minoría progresa a enfermedad hepática avanzada.
- La esteatosis aislada es un marcador de riesgo, no una enfermedad en sí misma, a diferencia de la MASH con fibrosis.
Objetivo del estudio:
- Diferenciar entre MASLD y MASH con fibrosis para una evaluación de riesgos y un manejo precisos.
- Guiar la vigilancia y la terapia dirigidas según la etapa de la enfermedad.
- Apoyar las estrategias de salud pública centradas en la salud metabólica y la prevención de la fibrosis.
Principales métodos:
- Revisión de las definiciones actuales y los datos de prevalencia global de MASLD y MASH.
- Análisis de los factores de riesgo de resultados hepáticos adversos en MASLD/MASH, incluida la estadificación de la fibrosis.
- Evaluación de las implicaciones terapéuticas basadas en la distinción entre esteatosis aislada y MASH con fibrosis.
Principales resultados:
- La prevalencia de MASLD es alta (25-30%), pero la MASH con fibrosis significativa es menos común (estimada en 5%).
- La etapa de fibrosis hepática, la gravedad de la disfunción metabólica y otros factores determinan los resultados adversos.
- La esteatosis aislada requiere manejo cardiometabólico, mientras que la MASH/fibrosis necesita intervenciones dirigidas al hígado.
Conclusiones:
- Distinguir entre esteatosis y MASH/fibrosis es crucial para una comunicación precisa de los riesgos y la asignación de recursos.
- Este cambio de paradigma permite estrategias de salud pública basadas en evidencia para la salud metabólica y la prevención de la fibrosis.
- El diagnóstico preciso guía la vigilancia y el tratamiento adecuados, previniendo la alarma innecesaria de los pacientes y la tensión en el sistema de salud.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:26Diseases of the Liver and Gallbladder
2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
1.3K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
1.3K
01:23Cirrhosis I: Introduction
32
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
32
01:24Cirrhosis II: Pathophysiology
53
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
53
01:20Cholecystitis
33
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
33
01:21Chronic Pancreatitis II: Pathophysiology
36
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
36